Please login to the form below
finerenone
This page shows the latest finerenone news and features for those working in and with pharma, biotech and healthcare.
Bayer’s finerenone scores FDA priority review for chronic kidney disease
Finerenone – also known as BAY 94-8862 – is a selective mineralocorticoid receptor antagonist (MRA). ... On the primary endpoint of kidney failure outcomes, patients treated with finerenone an 18% relative risk reduction compared to the placebo group.
Latest news
-
Xarelto and Eylea continue to dominate Bayer's pharma sales
They include five candidates in phase III trials: copanlisib for non-Hodgkin lymphoma, ODM-201 for hormone-sensitive prostate cancer, finerenone for diabetic kidney disease, vilaprisan for uterine fibroids and endriametosis
-
Xarelto leads the charge at Bayer
Investors asked Bayer to update on growth forecasts for pharma – particularly in light of some pipeline disappointments earlier this year involving pipeline drugs finerenone, vericiguat and molidustat as the company embarks
-
Bayer moves heart failure candidate finerenone into phase III
that adding finerenone to drugs such as ACE inhibitors or angiotensin II receptor antagonists seemed to reduce renal damage. ... If successful in these trials, finerenone could become the first MRA to be approved for DKD.
-
Bayer puts research at heart of business growth
finerenone and vericiguat for heart failure.
-
Bayer expects five drugs to enter phase III in 2015
These candidates include finerenone (BAY 94-8862), a mineralocorticoid receptor antagonist which the company is developing as an oral treatment for chronic heart failure.
More from news
Approximately 2 fully matching, plus 4 partially matching documents found.
Latest Intelligence
-
Heart failure therapy embarks on a new era
Bayer recently started three late-stage trials of its HF candidate finerenone - a mineralocorticoid drug designed as a safer replacement for older drugs in the class such as eplerenone and spironolactone,
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Account Executive, Medical/ Brand Communications, London
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
-
Consultant Dermatologist (Freelance)
-
£110-180ph
-
Senior Health Psychologist, London
-
Highly competitive salary
-
Head of Health Psychology, London
-
Highly competitive salary
- Scientists discover new approach to treat brain tumours
- Boehringer Ingelheim’s pulmonary fibrosis treatment produces promising phase 2 data
- BMA appoints two internal candidates to share the role of chief executive officer
- Taking a holistic approach to patient care
- Almirall and Evotec team up in multi-target dermatology alliance
- AstraZeneca and UK-based biotech company RQ BIO sign licencing agreement
- Innovative Medical Solutions for Postponing and Undoing Age-Related Disease
- Almirall and Evotec team up in multi-target dermatology alliance
- Moderna wins Prix Galien UK Award for best biotechnology product
- Why testing shouldn't be confined to the lab
- Leveraging Real-World Evidence for Cell and Gene Therapies
- Live Webinar: Engaging Patients "Just-In-Time" with Machine Learning
- Roche shares new positive Ocrevus data for MS patients
- How scientific storytelling can help Pharma cut through the noise
- Almirall and Evotec team up in multi-target dermatology alliance
- Christian Schade joins Aprea AB
- FDA approves Alexion’s Ultomiris for generalised myasthenia gravis
- First Herceptin biosimilar cleared in Europe
PMHub
Graphite Digital
We’re a digital CX agency collaborating with healthcare and pharmaceutical organisations to help them connect more deeply with their audiences...
Latest intelligence
- Leveraging Real-World Evidence for Cell and Gene Therapies
- Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
- Food Allergy – Is avoidance the only option?
- Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...
- Serious about sustainability?
- Get to know our new Sustainability Officer here at Cuttsy+Cuttsy...
